Appendix H. Excluded Studies

Breast Cancer


Gene expression profile testing of cancer tissue: Final evidence report–Appendix H


248. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systematic review of current development, evidence, and


434. Fitzal F, Filipits M, Rudas M, et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative


468. Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. *Cancer Investigation.* 2010;28(9):969-977. Exclude: No outcome of interest.


575. Hannouf MB, Xie B, Brackstone M, Zaric GS. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-

576. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. *Journal of Clinical Oncology*. 2006;24(13):2113-2122. Exclude: Date.


595. Health CAfDaTi. CADTH Rapid Response Reports. In: *Oncotype DX in Women and Men with ER-Positive, HER2-Negative Early Stage Breast Cancer who are Lymph Node Negative: A Review of Clinical Effectiveness and Guidelines*. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright (c) 2014 Canadian Agency for Drugs and Technologies in Health.; 2014.


959. Mayer EL, Vaz-Luis I, Richardson AL, et al. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)-


### Prostate Cancer


**Colon Cancer**


195. Little AS, Balmanno K, Sale MJ, et al. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer
Gene expression profile testing of cancer tissue: Final evidence report—Appendix H


312. Uemura A, Takehara T, Miyagi T, et al. Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. *Cancer Immunology, Immunotherapy*. 2010;59(3):453-463. Exclude: Not intervention of interest.


**Multiple Myeloma**


